The pharmaceutical sector continues to expand rapidly, driven by demand for innovative therapies in areas such as oncology, immunology, diabetes, and obesity, with total drug usage projected to exceed four trillion doses daily by 2030.
Within this environment, companies addressing ultra-rare conditions like refractory hypoglycemia caused by hyperinsulinism stand out for their potential to meet significant unmet medical needs while aligning with broader growth drivers in developed markets.
Rezolute’s Targeted Focus on Hyperinsulinism Disorders
Rezolute Inc.’s (RZLT:NASDAQ) late-stage development program centers on Ersodetug, a fully human monoclonal antibody designed to bind allosterically to the insulin receptor, thereby reducing over-activation from insulin and related substances to alleviate hypoglycemia symptoms.
This approach positions the therapy as potentially effective across congenital hyperinsulinism as well as acquired forms, including those linked to tumors or complications from bariatric and non-bariatric gastrointestinal surgeries.
Key Data Presentations from ENDO 2026
At the Annual Meeting of the Endocrine Society, the company delivered three poster presentations and one oral presentation by Huseyin Demirbilek, M.D., Professor in the Department of Pediatric Endocrinology at Hacettepe University Faculty of Medicine in Ankara, Turkey, and Principal Investigator of the Phase 3 sunRIZE study of ersodetug in congenital HI, covering data presentations.
Analyses of the natural history and adverse health and economic outcomes of congenital HI were featured in two posters, representing an important step toward consolidating and quantifying the disease impact and informing future health economics and outcomes research that will facilitate the development and potential future launch of the company’s therapy, Ersodetug, in this indication.
A third poster highlighted favorable outcomes from a case series of nine patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors, where 75% of patients receiving IV dextrose/total parenteral nutrition in the expanded access program achieved complete discontinuation of that support.
Supporting Evidence from Ongoing Clinical Programs
Brian Roberts, M.D., and Chief Medical Officer at Rezolute, noted the value of showcasing progress across the two late-stage programs in congenital and tumor HI, with deeper analyses of the sunRIZE data demonstrating meaningful therapeutic benefit further supported by positive outcomes in the expanded access program and interim and preliminary Phase 3 upLIFT study observations in tumor HI patients.
The natural history outcomes studies also underscore the significant clinical outcomes impacts of this disease and the urgent need for improved treatment options.
Industry Trends Shaping Biotech Development
Iqvia discussed the global pharma market projection for 2026, emphasizing that the largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity.
Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, “2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024.”
BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, “Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access.”
Perspectives and Valuation Outlook
On June 15, 2026, Douglas Tsao of H.C. Wainwright & Co. issued a “Buy” rating with a price target of US$5, expressing increased confidence in Ersodetug’s opportunity in congenital hyperinsulinism following discussions with clinicians after the company’s oral presentation of the sunRIZE data at ENDO 2026.
Tsao also highlighted continued upside potential in the tumor hyperinsulinism program, noting that Rezolute expects to read out data from its Phase 3 study, which uses a more objective continuous glucose infusion rate endpoint, in the second half of 2026.
Chen Lin of What is Chen Buying? What is Chen Selling? observed on June 16, 2026, that biotechs are experiencing a nice rebound, with RZLT shares jumping on interim data and an upgrade by Guggenheim with a target of US$11.
Share Structure and Forward Milestones
Rezolute Inc. has a market cap of US$461.24 million, with 96.29 million shares outstanding and a 52-week range of US$1.07-US$11.46.
Institutions own 90.03% of shares, while Management & Insiders own 9.68%. The remaining 0.29% of shares are Retail.
According to Rezolute’s investor presentation, the company expects to provide an update on its sunRIZE study and FDA submission in the second half of 2026, offering retail investors additional clarity on the path forward for this late-stage asset.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports’ newsletter. | Subscribe |
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.